【摘要】 目的 分析交叉抗原表達的急性白血病的臨床特征及緩解率。 方法 對2009年10月-2010年11月血液內科的210例交叉表達髓系和淋巴細胞系相關抗原的初治急性白血病患者的標本，采用流式細胞術檢測白血病細胞的免疫表型，根據免疫標記和FAB（French、American、Britain）分型進行分組，分析其異質性的生物學特征和影響緩解率的相關因素。 結果 210例急性白血病的FAB分型以AML-M1/M2（82例）和ALL（78例）為主；免疫分型以B淋巴細胞系和髓系混合表達多見（116例），其中CD34表達率高達91.4%（192例）， CD7表達率為50.5%（106例），且與CD34相關（P=0.04）；出現CD34、CD7、CD19三者共表達的患者緩解率較低（9.09%）。 結論 交叉抗原表達的急性白血病的診斷有賴于免疫分型的判斷，其分化抗原的表達類型是影響其緩解率的重要因素。【Abstract】 Objective To observe the clinical characters of acute leukemia with cross-lineage antigen expression and analyze the remission rate. Methods Between October 2009 and November 2010, 210 patients were diagnosed and classified by morphology. Cytochemistry and immunology were used to analyze the immunophenotype. According to the immunostaining relative factors and FAB (French, American, and Britain) phenotype standard, the samples were divided into several groups. The conical characters and relative factors of remission rate were analyzed. Results In 210 patients with cross-lineage antigen expression, AL, AML-M1/M2 (82 cases) and ALL (78 cases) were common in FAB phenotype,and cross-lineage of B lineage and myelolineage were common in immunotype (116 cases). CD34 got the highest expression frequency of all (192 cases),and had the most important effect on patients′ prognosis. CD7 was also positive commonly (106 cases) and related with CD34 (P=0.04). So it′s significant for the outcome. The patients who got co-expression of CD34, CD7 and CD19 had worse prognoses. Conclusions Acute leukemia with cross-lineage antigen expression is a special type and is confirmed by immunotype. Furthermore, expression types of differentiation antigen are critical for the prognosis.
ObjectiveTo summarize the research progress of hepatocellular carcinoma (HCC) based on tumor microenvironment immunophenotyping.MethodThe related literatures of basic and clinical studies on HCC immunophenotyping in the recent years were reviewed.ResultsHCC could be divided into different immunophenotypes based on tumor microenvironment, and it showed different immune molecular characteristics, immune cell infiltration characteristics, and anti-tumor ability. At the same time, the HCC immunophenotype was significantly associated with patients’ survival and had been proved to be able to better evaluate the prognosis of HCC patients. According to the relevant molecular characteristics in the HCC immune microenvironment, it could provide guidance for the drug regimen of immunotherapy.ConclusionHCC immunophenotyping is still in the early stage of research, and its clinical application value has been preliminarily shown for the evaluation of patients’ prognosis and immunotherapy decision-making, which is a new idea of individualized treatment of HCC in the future.